AZN
Astrazeneca plc
$195.15+6.14%
Setup
Watch
Buy Zone
$193.22-$202.88
Sector
Drug Manufacturers - General
Industry
Drug Manufacturers - General
44
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
AZN chart
Loading chart…
Overall Quality44
RS Rating
67
relative strength
Fundamentals
66
Solid fund-Q
Volume Demand
82
+20% vs avg
Technical Setup
75
6/8 checks
Industry/Theme
91
Drug Manufacturers - General
Trade Plan
Avoid
Entry
$193.22
Entry Zone
$193.22-$202.88
Stop / Risk
$177.76
RS Rating
67
Volume confirmed
Yes
Targets
$231.86 / $241.53
Breakout · IBD Setup
4 ✓ 4 ✗
Entry $193.22–$202.88Stop $177.76Target $231.86 / $241.53
Market regimeRange
Quality44
RS Rating67
Above 50-MA+5.95%
Above 200-MA+6.88%
VolumeConfirmed
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
44
MarketRange
SetupWatch
ConfidenceExperimental · not backtested
Fund-Q66 · Solid
StatusAvoid
Stock Data
52-Week Range135 – 213
Price % Chg YTD11.2%
Price % Chg 4wk9.97%
50-Day Avg Vol2.0 Mil
P/E Ratio28.3
Market Cap$292B
SectorHealthcare
IndustryDrug Manufacturers - General
Company Fundamentals
EPS % Chg (Qtr)5.63%
Sales % Chg (Qtr)12.51%
EPS Growth 5y22.05%
Sales Growth 5y16.31%
Annual ROE23.51%
Gross Margin74.32%
Operating Margin23.23%
Net Margin17.19%
Debt / Equity0.72
Setup levels
Current price
$195.15
Pivot
$193.22
Distance to buy
-8.3%
52-week range
134.9-212.72
Trigger evidence
No active trigger evidence available.
Pattern levels: near highs
Financial health checks
5/5
Return on equity above 15%
ROE 23.51%
Net margin above 10%
Net margin 17.19%
EPS growing quarter on quarter
EPS q/q 5.63%
Sales growing quarter on quarter
Sales q/q 12.51%
Debt to equity below 1.0
D/E 0.72
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE23.51%
vs sector +0.5%
Net margin17.19%
vs sector -2.1%
Gross margin74.32%
vs sector +2.7%
EPS growth q/q5.63%
vs sector -13.6%
Sales growth q/q12.51%
vs sector -8.7%
Debt / equity0.72
vs sector +0.00
Business quality
66
GradeSolid
EPS rating47
P/E28.3
Market cap$292B
IndustryDrug Manufacturers - General
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Pass
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-07-03
Trigger date
—
Days on list
1
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.